TargetBeta
FSHR
follicle stimulating hormone receptor · also FSHRO, LGR1, ODG1 · Glycoprotein hormone receptors
3 programs in company-led studies act on FSHR, from 3 companies: 1 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| follitropin alfarule | Merck KGaA, Darmstadt, Germany | phase 4 | 263 running | – | ChEMBL |
| Follicle Stimulating Hormonerule | Glycotope | phase 4 | 61 running | – | ChEMBL |
| follitropin deltarule | Ferring Pharmaceuticals | phase 3 | 181 running | – | ChEMBL |
Conditions their studies are in
- Infertility, 3 programs
- Infertility, Female, 3 programs
- Anovulation, 1 program
- Hypogonadism, 1 program
- Oligospermia, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Sep 30, 2027follitropin alfa · Merck KGaA, Darmstadt, Germany · phase 4 · NCT07340827
- Oct 15, 2027Follicle Stimulating Hormone · Glycotope · phase 4 · NCT07862725
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.